This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
If successful, the drug is forecasted to reach sales of $63.5 According to the pre-IND meeting with the US Food and Drug Administration (FDA), Luye Pharma plans to submit the New Drug Application (NDA) for LY03010 to the FDA through the 505(b)(2) pathway. million in 2031, representing 0.6
It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. Continued competitive intensity. The first in class launches barely have time to establish before they face competition, and then the competition keeps on coming.
In this episode, Samuel Adeyinka interviews John Crowder who covers how to sell effectively in medical sales. Tune in now and get medical sales-ready! — Watch the episode here Listen to the podcast here Selling Effectively In Medical Sales With John Crowder We have with us another special guest. I’m wonderful.
It’s no secret that being a medical sales rep is a difficult, but rewarding, profession. Sales reps are usually at the forefront of this pressure and have to work hard to make sure the product’s value is understood while adhering to the FDA regulations. Pick Your Medical Device Sales Tech Wisely. Web Conferencing Tool.
Diagnostic testing sales: where meticulous detail meets the human touch, changing the course of cancer care one relationship at a time. In this special episode for Breast Cancer Awareness Month, Veronica Vasek uncovers the challenges, triumphs, and the vital role that diagnostic sales reps play in the healthcare landscape.
The FDA needs to study what people do when they see a DTC ad. Drug pricing is done by internal teams who look at what the market will bear and the competitive landscape. Some DTC budgets are only released when certain sales targets are hit. SUMMARY: DTC marketing is not the reason why prescription drugs cost so much.
In the fast-paced world of medical sales, keeping an eye on your competitors is essential. You and I both know that competitive intelligence —knowing what your rivals are doing, how they’re positioning their products, and understanding market trends—can make all the difference. What used to take days, AI now handles in no time.
In trying to save the product, Biogen’s reputation was trashed by FDA advisors, HCPs, and the healthcare media. 2wo: The competition’s MS drugs were better – The MS market is lucrative, and competitors launched products that were better than Biogen’s with fewer side effects discussed by the MS community online.
Being a specialist in the medical sales field is no small feat because you have to really hone in on the nuances of that particular niche. That is what Shirley Taylor has done in the as a mammography sales specialist, focusing on breast imaging sales. Breast Imaging Sales With Shirley Taylor Part 1. That’s my niche.
Building your brand in medical device sales requires experience, strategic insights, and a relentless pursuit of excellence. With 40 years of medical device sales experience, Pat discusses how to build a successful medical device sales business. He also touches on the sales funnel, the art of hiring, and more.
He provides a fascinating glimpse into what it takes to excel in the field of medical device sales, emphasizing the importance of authenticity and passion. Blake has a unique case because he was a cardiac, cath lab, critical care, and surgery nurse who got into medical sales. People come from sales, clinical, and engineers.
The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). Sustainable biosimilar competition in Europe: can it be achieved? US sales of Stelara totalled $6.4 billion in 2022, according to J&J’s financial results.
Introduction Sales enablement is transforming, driven by advancements in artificial intelligence (AI). Traditional sales training methods, while foundational, often fall short in delivering the speed, personalization, and realism required in today’s competitive market. Section 1: AI-Driven Onboarding for Sales Teams 1.1
In the world of medical device marketing and sales, executing a well thought through product launch provides a huge opportunity to gain market share, grow your clientele, and increase your revenue. Plan Ahead Before FDA Approval. With an unpredictable FDA timeline, the launch date could come sooner than you think.
There’s no shortage of challenges for those new to pharma, medical sales and even veterans. Often we’re lucky if we even get to see our physicians, let alone overcome their objections regarding insurance coverage and competitive claims. Below are seven common challenges that pharmaceutical and other medical sales reps face.
Knowing what’s to come in the medical sales industry is not only interesting, but it could help you with your sales goals. If you know how to prepare and get ahead of your competition, reaching your goals will be that much easier. What does this mean for the medical sales representatives?
According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 percent from $3.45 trillion in Q2 2022 to $3.14 trillion in Q3 2022. percent and 24.2 percent and 16.2
As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.
I have been fortunate to work with developing reps, generating sales, and making connections with surgeons. Was it med sales from the beginning? Was it med sales when you were a younger man and you said, “I always want to do that?” What medical sales stuff did you do before you started the schooling and the teaching that you do?
As competition in the healthcare space intensifies, pharma brands that fail to integrate AI risk falling behind. Predict physician prescribing patterns to optimize sales outreach. AI-Powered Email Automation for Pharma Sales Teams AI improves email marketing by: Segmenting HCPs and patients based on engagement history.
Pharma marketing executives face unique challenges like regulatory restrictions, stiff competition, and shifting consumer expectations. So, how can you build trust, boost brand awareness, and still drive sales? Follow FDA guidelines on advertising to ensure your messaging is accurate and ethical.
The world of medical sales is bursting with change. This presents a dynamic environment for whether you are an aspiring and seasoned medical sales rep. By understanding the evolving landscape, both parties can ensure they’re equipped to navigate the exciting future of medical sales.
In the sales world, every industry has its unique challenges, and healthcare is no different. However, creating a strong sales strategy in healthcare is crucial because it affects patient care and the adoption of new medical solutions. In this article, our team at Rep-Lite will show you “How to build a healthcare sales machine?”
A strong medical sales team is essential for success in the healthcare industry. These teams not only drive product sales but also build lasting relationships with healthcare professionals, helping deliver innovative medical solutions to those who need them most. Let Us Build You A Medical Sales Machine Today!
The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus BioSciences’ Cimerli – which its developer claims is the first to be fully interchangeable with the originator product. billion in sales from it in 2021, while Novartis made $2.2
Did you know that a well-trained pharmaceutical sales rep can be the driving force behind a healthcare provider's decision-making process? Welcome to the world where sales training isn't just a formality. In this post, we’re diving deep into the realm of pharmaceutical sales training. That’s right.
B2B sales consulting for medical sales is a specialized service that helps healthcare organizations navigate the unique challenges of B2B transactions within the healthcare industry. What is B2B Sales Consulting? A sales expert in this space needs to understand these intricacies and provide tailored solutions.
Medical sales representatives are the medium through which medical companies sell their healthcare products to providers like hospitals and clinics. Medical sales rep requirements include technical knowledge of medical equipment and technologies, sales skills, and interpersonal abilities. Why Pursue a Career in Medical Sales?
Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. Submission for US FDA regulatory approval, anticipated to be received by the end of 2023, further drove this progress, GlobalData noted.
per share deal includes $8 per share upfront, worth around $576 million, with the remainder in the form of a contingent value right (CVR) that will be paid to Concert shareholders if deuroxilitinib meets certain sales targets within a set time limit. The $11.50
The FDA is planning to take an additional three months to review Biogen’s experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April. There was no update from Biogen on whether the FDA will require an advisory committee meeting to review the data with the drug.
Begin Preparation Before FDA Approval. Before marketing the device, a pre-market submission and approval are required by Food and Drug Administration FDA. The launch date may be closer than you believe with the FDA’s unpredictable timeframe. Complete product documentation and make it easily accessible. Train Your Staff.
The Future of the Medical Sales Profession: Challenges and Approaches in a Fast-Changing Healthcare Market. Medical sales representatives are professionals who promote medical and health related products or services to healthcare providers, such as hospitals, clinics, pharmacies, and doctors.
Food and Drug Administration (FDA) announced the clearance of Dexcom’s device, marking it as the first continuous glucose monitor available over the counter. The company aims to offer the device at a competitive price point, but further pricing details will be shared closer to the product’s release date. Are you hiring?
Generic Drug Launches This year could see up to 50 generic drug approvals on brand pharmaceuticals worth more than $20 billion in sales, Casberg noted. billion in sales. The product had sales of roughly $800 million per year. The drug generated $2 billion in sales last year. “We’re
In todays competitive market, where digital strategies and patient-centric approaches are essential, having an expert partner is more critical than ever. The Value of an Expert Partner: Industry-Specific Expertise: Pharmaceutical marketing companies know the ins and outs of marketing drugs, from branded drug launches to FDA regulations.
The FDA has given a green light to Roche’s CD20xCD3 bispecific antibody Lunsumio as a treatment for relapsed or refractory follicular lymphoma, following the lead of the European Commission which cleared the drug in June. Some analysts agree, pitching peak sales at $2 billion or more.
Despite receding sales, Comirnaty, its partnered COVID-19 vaccine with BioNTech, is still forecast to reach the analyst consensus global forecast sales of $33 billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. billion on Dec 31, 2022. Merck & Co. billion to $281.3 and 31.6%, respectively.
The research recognised 15 late-stage experimental treatments forecast to deliver annual sales of over $1 billion within five years, including a wide range of therapeutic developments for rare diseases and difficult-to-treat conditions, including HIV, Parkinson’s, and cancer. Lecanemab (BAN2401) developed by Eisai Co Ltd and Biogen Inc.
China’s Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks. Analysts at GlobalData said last year that they expect LY03010 to launch in 2024 and bring in sales of around $64 million in 2030.
The FDA granted the drug an accelerated review with a verdict expected by 25 January. ” The new data will no doubt be debated extensively at a yet-to-be-scheduled FDA advisory committee meeting, and Biogen will be hoping for a better outcome than at the Aduhelm meeting, which resulted in a vote against approval of the drug.
Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year.
The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The FDA also awarded priority review for Eli Lilly’s donanemab, a monoclonal antibody for Alzheimer’s disease, in August 2022, and the company expects approval by February 2023. trillion in Q2 2022 to $3.14
Clovis Oncology has said it may not have enough cash to fund continuing operations beyond January next year, as it struggles to reverse a decline in sales of PARP inhibitor Rubraca. Sales were around $140 million in 2019, and climbed to $165 million the following year, despite the impact of the pandemic.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content